Live: Will AeroVironment (AVAV) Beat Q3 Earnings Tonight
AVAV is set to report Q3 results after the close. Analysts expect revenue around $203 million and non-GAAP EPS near $...
Which Cards Offer Highest Cash Back Without Fees
Explore which cards offer the highest cash back without fees, ensuring you get the most out of your spending.
27,400 articlesDividend Safety Check: VGIT Outlook for 2026 Investors
VGIT remains a stable Treasury income option as yields swing with policy signals. This report analyzes how duration r...
Dave Ramsey: You Make $140K, Cut Luxuries Now or Else
A caller earning $140K on The Dave Ramsey Show exposes how discretionary debt can erode cash flow, underscoring a bro...
Broadcom Marvell: Broadcom’s Custom Silicon Dominance
Broadcom’s custom silicon advantage dominates the AI hardware beat, delivering outsized revenue growth while Marvell ...
Wells Fargo Raises Targets on UNFI as MTDR Gains Follow
Analysts boosted targets on UNFI and MTDR after solid quarterly results, signaling renewed investor optimism as pipel...
NVIDIA’s Trillion-Run Rewriting the Rules of Tech Investing
NVIDIA’s market value has climbed into the multi-trillion-dollar club as AI demand powers surge in revenue and margin...
UPS Falls 11% as FedEx Just Stole the Crown
UPS sinks about 11% after weaker quarterly results, while FedEx surges past UPS in market value following a stronger ...
Micron Delivers Strong Earnings, Elevates Full-Year Guidance
Micron Technology reports a robust third quarter, beating expectations and raising guidance amid a fraught memory mar...
Buying Archer Aviation (ACHR) Stock Could 10X Net Worth
Archer Aviation is venturing into urban air mobility with electric VTOL aircraft. This piece analyzes the case for bu...
Luxury Housing’s Market Resilience: A Divergent Cycle
Top-tier buyers are steering a different cycle as higher rates soften the broader market. Wealth migration and long-t...
Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Barclays Thinks Ionis Headed Toward a $106 Target This Year
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status